Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
UCB plans to submit regulatory applications in Q3 2022
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
Subscribe To Our Newsletter & Stay Updated
